News
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
4d
Pharmaceutical Technology on MSNBharat Biotech acquires licence for GSK’s Shigella vaccine developmentGSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...
Explore more
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results